Reuters logo
BRIEF-Novartis says Zykadia drug gets FDA priority review
February 23, 2017 / 6:21 AM / 8 months ago

BRIEF-Novartis says Zykadia drug gets FDA priority review

Feb 23 (Reuters) - Novartis AG

* Novartis drug zykadia receives fda priority review for first-line use in patients with alk+ metastatic nsclc

* Says novartis drug zykadia receives fda priority review for first-line use in patients with alk+ metastatic nsclc

* Says fda also grants breakthrough therapy designation based on phase iii data in previously untreated alk+ metastatic nsclc patients with metastases to brain Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below